Jorianne E. Boers

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 16, 2024

New and Interesting Fungi. 7.

New and Interesting Fungi. 7.

Journal: Fungal systematics and evolution

Published: April 09, 2024

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: December 18, 2023

New and Interesting Fungi. 6.

New and Interesting Fungi. 6.

Journal: Fungal systematics and evolution

Published: April 24, 2023

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Journal: Nature cancer

Published: October 09, 2022

New and Interesting Fungi. 5.

New and Interesting Fungi. 5.

Journal: Fungal systematics and evolution

Published: June 21, 2022

Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.

Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 18, 2022

Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer.

Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: June 18, 2021

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.

Journal: Clinical nuclear medicine

Published: November 12, 2020

Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study.

Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 14, 2020

Image Quality and Interpretation of [18F]-FES-PET: Is There any Effect of Food Intake?

Image Quality and Interpretation of [18F]-FES-PET: Is There any Effect of Food Intake?

Journal: Diagnostics (Basel, Switzerland)

Published: August 29, 2020

Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.

Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 13, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026